AI assistant
Verona Pharma plc — Director's Dealing 2025
May 2, 2025
30667_dirs_2025-05-01_9b46712f-b3c0-4ea0-8991-a6e46add052a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2025-04-29
Reporting Person: Sinha Vikas (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-04-29 | Ordinary Shares | M | 15048 | $1.7 | Acquired | 89488 | Direct |
| 2025-04-29 | Ordinary Shares | S | 15048 | $8.9208 | Disposed | 74440 | Direct |
| 2025-04-29 | Ordinary Shares | M | 4952 | $0.5038 | Acquired | 79392 | Direct |
| 2025-04-29 | Ordinary Shares | S | 4952 | $8.9208 | Disposed | 74440 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-04-29 | Share Options (Right to Buy) | $1.7 | M | 15048 | Disposed | 2027-04-26 | Ordinary Shares (15048) | Direct |
| 2025-04-29 | Share Options (Right to Buy) | $0.5038 | M | 4952 | Disposed | 2032-04-27 | Ordinary Shares (4952) | Direct |
Footnotes
F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on November 6, 2024, solely with the intent to cover payment of the exercise price.
F3: Consists of 74,440 Ordinary Shares represented by 9,305 ADSs.
F4: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F5: The option is fully vested.